Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(67%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
2
67%
Ph phase_2
1
33%

Phase Distribution

0

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
N/ANon-phased studies
2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Completed(1)

Detailed Status

Recruiting2
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
2
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 21 (33.3%)
N/A2 (66.7%)

Trials by Status

recruiting267%
completed133%

Recent Activity

2 active trials
Showing 3 of 3
recruitingphase_2

Multicenter, Single-Arm, Prospective Phase II Study of Neoadjuvant Cryo-Thermal Ablation Combined With Toripalimab and Chemotherapy for Resectable Stage IB-IIIB Non-Small Cell Lung Cancer

NCT07855965
recruitingnot_applicable

Ablation Compare With Surgery for Early Breast Cancer

NCT07484087
completednot_applicable

EUS-Guided Cryothermal Ablation in Patients With Stage III Pancreatic Adenocarcinoma (HybridTherm Study)

NCT02336672

Clinical Trials (3)

Showing 3 of 3 trials
NCT07855965Phase 2

Multicenter, Single-Arm, Prospective Phase II Study of Neoadjuvant Cryo-Thermal Ablation Combined With Toripalimab and Chemotherapy for Resectable Stage IB-IIIB Non-Small Cell Lung Cancer

Recruiting
NCT07484087Not Applicable

Ablation Compare With Surgery for Early Breast Cancer

Recruiting
NCT02336672Not Applicable

EUS-Guided Cryothermal Ablation in Patients With Stage III Pancreatic Adenocarcinoma (HybridTherm Study)

Completed

All 3 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
3